GS-3242 clinical trials
GS-3242 is named as an intervention in 3 current clinical trials in our USA, Canada and Australia registers. 3 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Gilead Sciences. The most-studied condition is HIV-1-infection. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for GS-3242
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of GS-3242
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
NCT07708727 · HIV-1-infection
|
Phase 2/3 | Recruiting | Gilead Sciences | USA, Canada |
|
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287 · HIV-1-infection
|
Phase 2 | Recruiting | Gilead Sciences | USA, Canada, Australia |
|
Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels
NCT07841990 · ClinicalTrials.gov ↗ · HIV-1 Infection
|
Phase 2 | Recruiting | Gilead Sciences | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
GS-3242 in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing GS-3242. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination with Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1
2026-526026-40-00 · CTIS ↗ · Virus Diseases
|
Phase 3 | Ongoing | Gilead Sciences Inc | Portugal, Poland, Germany + 2 more |
Conditions studied with GS-3242
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Gilead Sciences | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 3 |
| Clinical trials in Canada | 2 | 2 |
| Clinical trials in Australia | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about GS-3242 trials
How many clinical trials are testing GS-3242?
3 current trials in our USA, Canada and Australia registers name GS-3242 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are GS-3242 trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 3 with sites in USA, 2 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors GS-3242 clinical trials?
The lead sponsor is Gilead Sciences. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how GS-3242 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GS-3242 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GS-3242 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.